ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Takeda expects to launch a better dengue vaccine

Japanese pharmaceutical sees the neutralizer benefiting young children

Rajeev Venkayya, president of Takeda Pharmaceutical’s global vaccine business

TOKYO -- Nearly 400,000 people come down with dengue fever every year. The mosquito-borne tropical disease appears especially fond of Asia, which accounts for 70% of the infections. While France's Sanofi licensed the first dengue vaccine in 2015, the counteractant has been ineffective for young children. 

Rajeev Venkayya, president of Takeda Pharmaceutical's global vaccine business, expects a new neutralizer to fill the gap in Asia.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more